Desmopressin and bleeding risk after percutaneous kidney biopsy

BMC Nephrology

Table 2 Association of the study outcomes with DDAVP use

Outcome	DDAVP Arm		No DDAVP Arm		P	ES	95% CI	P_adj
Outcome	Mean / N	SD / %	Mean / N	SD / %	P	ES	95% CI	P_adj
Post Biopsy SBP (mmHg)	129.89	16.13	129.91	18.27	0.99	−1.02	−6.83 - 4.79	0.73
Post Biopsy DBP (mmHg)	73.64	10.56	75.13	10.74	0.23	−3.55	−6.96 - -0.14	0.04
ΔSBP (mmHg)	2.77	12.21	4.15	13.79	0.38	−2.93	−7.24 - 1.38	0.18
ΔDBP (mmHg)	2.78	10.31	1.85	8.86	0.40	−0.27	−3.16 - 2.62	0.86
Post Biopsy Hemoglobin (g/dl)	9.48	1.71	11.17	1.82	< 0.001	−0.64	−1.18 - -0.11	0.02
ΔHemoglobin (g/dl)	0.90	0.82	0.36	0.76	< 0.001	0.58	0.32–0.83	< 0.001
Hb drop by ≥1 g/dl	49	44.14	40	18.96	< 0.001	3.44	1.69–6.99	< 0.001
Hematoma	20	18.02	32	15.17	0.51	2.53	1.08–5.94	0.03
Hematuria	10	10.64	6	3.17	0.01	5.12	0.77–34.09	0.09
RBC transfusion needed	5	4.50	1	0.47	0.02^a	1.18	0.09–16.32	0.90
Bleeding event	66	59.46	67	31.75	< 0.001	3.88	1.95–7.74	< 0.001
Length of stay (d)	5.23	6.82	3.02	3.02	< 0.001	0.89	−0.49 - 2.27	0.20

SBP Systolic blood pressure, DBP Diastolic blood pressure, ES Effect size – represented as mean difference for continuous variables and odds ratio for dichotomous variables; P_adj – Significance value after adjusting for the propensity score; ^a, due to small cell numbers Fisher’s exact test was used

ISSN: 1471-2369